<DOC>
	<DOCNO>NCT01624493</DOCNO>
	<brief_summary>This phase I/II trial determine recommend dose activity BNC105P patient partially platinum sensitive ovarian cancer first second relapse .</brief_summary>
	<brief_title>BNC105P Combination Study Partially Platinum Sensitive Ovarian Cancer Patients</brief_title>
	<detailed_description>OUTLINE : This multi-center study . BNC105P novel vascular disrupt agent ( VDA ) promise preclinical activity combine platinum gemcitabine . The result standard chemotherapy carboplatin gemcitabine ovarian cancer relapse within 12 month initial platinum-based regimen require improvement . This trial determine recommend dose activity BNC105P administer carboplatin gemcitabine . PHASE I : This trial use standard 3+3 design allocate participant start dose level Phase I . If dose level 1 deem acceptable toxicity dose level 2a 2b opened time . Dose level 3 open dose level 2a 2b deem acceptable toxicity . The underlying assumption determine recommended dos triple combination carboplatin , gemcitabine BNC105P likely minimum dos require agent carboplatin AUC 4 , gemcitabine 800 mg/m2 BNC105P 12 mg/m2 . This correspond dose level 1 . PHASE II 1:1 RANDOMIZATION : Carboplatin AUC 4 day 1 , gemcitabine 800 1000 mg/m2 day 1 8 21 day cycle maximum 6 cycle . OR Carboplatin AUC 4 day 1 , gemcitabine 800 1000 mg/m2 day 1 day 8 dose BNC105P determine phase I , day 2 9 21 day cycle maximum 6 cycle , follow single agent maintenance BNC105P 16 mg/m2 maximum 6 additional cycle Minimum follow 12 month ECOG Performance Status Phase I : 0-1 ; ECOG Performance Status Phase II : 0-2 Life Expectancy : Less 12 week Hematopoietic ( phase ) : - Platelet count ≥ 100 x 109/L - ANC ≥ 1.5 x 109/L - Haemoglobin &gt; 9g/dl ( post transfusion ) - INR ≤ 1.5 x ULN Hepatic ( phase ) : - Total Bilirubin ≤ 1.5 x upper limit normal ( ULN ) - ALT ≤ 2.5 x ULN Renal ( phase ) : - Creatinine clearance ≥ 55 mL/min accord Cockcroft Gault formula - If Calculated GFR 50 - 54 mL/min isotopic GFR may perform . If isotopic GFR &gt; 55ml/min , patient eligible study calculate GFR use dose calculation . Cardiovascular ( phase ) : - Normal leave ventricular ejection fraction ( LVEF ) , i.e . ≥ 50 % Gated Heart Pool Scan , fractional shorten echocardiogram ≥ institutional LLN perform within 2 month prior randomisation - Corrected QTc &lt; 470 msec ECG perform within 4 week prior randomisation .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria Phase I Only : Histologically cytologically proven diagnosis epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer , include histological subtypes carcinosarcoma . Inclusion Criteria Phase II Only : Histologically proven diagnosis epithelial ovarian cancer , primary peritoneal cancer fallopian tube cancer . Progressionfree interval 4 9 month first line chemotherapy 4 12 month secondline chemotherapy platinum ( cisplatin carboplatin ) base regimen . Subjects must progress ( base GCIG CA125 and/or RECIST criterion ) last platinum base regimen . Subjects must assessable response base GCIG CA125 and/or RECIST criterion . Subjects clinically evident ascites and/or pleural effusion must assessable RECIST . Study treatment plan able start within 7 day randomisation Exclusion Criteria Phases I II : Nonepithelial ovarian cancer ovarian tumour low malignant potential ( borderline tumour ) More two prior chemotherapy regimens ovarian cancer ( exclude hormonal therapy biologic agent ) . Any prior chemotherapy cancer , &gt; 10 year permit phase II , except high dose chemotherapy/autologous allogeneic transplantation Chemotherapy within 20 day prior registration . Hormonal therapy biologic therapy within 28 day prior registration Concurrent treatment experimental drug anticancer therapy . Concurrent treatment clopidogrel , ticlopidine , persantin antiplatelet agent Radiotherapy within 21 day prior registration , great 15 % bone marrow . Persistent toxic effect previous chemotherapy great Grade 1 severity ( CTCAE v 4 , appendix 8 ) Known brain leptomeningeal disease ( baseline CT brain MRI require clinical suspicion central nervous system involvement ) . Subjects invasive malignancy ( ) evidence another cancer present within last 3 year , exception early stage nonmelanoma skin cancer , carcinoma situ cervix , synchronous endometrial cancer ( stage 1 G1,2 ) Untreated and/or uncontrolled cardiovascular condition and/or symptomatic cardiac dysfunction ( unstable angina , congestive cardiac failure , myocardial infarction ) within previous year , cardiac ventricular arrhythmia require medication , history 2nd 3rd degree atrioventricular conduction defect . Cerebrovascular accident transient ischemic attack within 6 month prior registration . Poorly control hypertension : systolic BP &gt; 150 diastolic BP &gt; 100 mmHg . Antihypertensive medication permit BP must ≤150 systolic ≤100 diastolic 2 reading separate least 24 hour . Deep vein thrombosis , pulmonary embolism , within 6 month registration arterial thrombosis , arterial embolism within 12 month prior registration . Receiving full dose , therapeutic anticoagulation warfarin , related oral anticoagulant unfractionated low molecular weight heparin . Low dose heparin give prophylaxis , aspirin dose ≤ 325 mg/day acceptable . Significant infection include active hepatitis B , hepatitis C abnormal liver function test , HIV . Testing mandatory . Screening Hepatitis B per institutional policy . Patients know Hep B surface antigen positive eligible even antiviral treatment . Serious medical psychiatric condition might prevent management accord protocol . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomisation Pregnancy , lactation , inadequate contraception . Women must post menopausal sterile , use two reliable mean contraception . Women childbearing potential must pregnancy test take proven negative within 7 day prior registration . Life expectancy le 12 week . Exclusion Criteria Phase II : Carcinosarcoma mucinous carcinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vascular Disrupting Agents</keyword>
	<keyword>BNC105P</keyword>
	<keyword>Partially platinum sensitive</keyword>
</DOC>